EyePoint Pharmaceuticals (EYPT) Misses Q1 EPS by 17c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q1 EPS of ($0.99), $0.17 worse than the analyst estimate of ($0.82). Revenue for the quarter came in at $696 thousand versus the consensus estimate of $1.01 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• salesforce.com (CRM) Reiterated at Market Outperform by Citizens: Acquiring Fin
• Taysha Gene Therapies (TSHA) PT Raised to $11 at Citizens on REVEAL Data Update